Gunnar Saelid, CEO of Lytix Biopharma, said: “The company has made significant progress in 2008, initiating full preclinical development activities for two important projects. LTX-109 is a novel antimicrobial compound that is effective against a broad range of pathogens. In oncology, LTX-315 (oncopore) is a product aimed at the treatment of solid tumors, potentially in combination with existing therapies.
“Oncopore is currently in preclinical development and has proven efficacy across a range of 40 tumor cell lines, including lines resistant to established chemotherapy. Both LTX-109 and LTX-315 will enter the clinical phases during the latter half of 2009.”